Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate tirofiban concentration in the blood over a period of 24 hours after tirofiban administration. Subjects with varying degrees of renal insufficiency (i.e. kidney function) will be included in the study. Tirofiban is known to be cleared from the blood by the kidneys and so people with kidney problems clear tirofiban to a slower extent compared to people without kidney problems. By comparing the tirofiban concentration profile between subjects with healthy kidney function versus with impaired kidney function, a tirofiban dosing recommendation for subjects with impaired kidney function can be made.
This is a non-randomized, single-center, open-label study. A single dose of tirofiban (25 µg/kg administered intravenously over a 3 min period) will be administered to subjects with normal renal function (>90 mL/min CrCl), moderate (30-59 mL/min CrCl), and severe (<30 mL/min CrCl) renal impairment with non-dialysis-dependent renal insufficiency
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
Tirofiban is cleared from the plasma largely by renal excretion. As a consequence, a dosage adjustment of 50% of the tirofiban label dosing regimen (0.4 μg/kg/min for a period of 30 minutes, followed by an infusion of 0.10 μg/kg/min) is recommended in patients with severe renal impairment (<30 mL/min CrCl), including those who require hemodialysis. The dosage adjustment for the tirofiban high-dose bolus regimen (25 μg/kg bolus followed by a 0.15 μg/kg/min maintenance) for patients with varying degrees of renal insufficiency is however unknown. The purpose of this study is to determine the extent of dosage adjustment for the high-dose bolus regimen for patients with moderate (30-59 mL/min CrCl), and severe (<30 mL/min CrCl) renal insufficiency.
This non-randomized, single-center, open-label study evaluating the pharmacokinetic (PK), pharmacodynamic (PD), and safety profile of a single high-dose IV bolus injection of tirofiban (25 µg/kg). A single dose of tirofiban will be administered to the subjects with normal renal function (>90 mL/min CrCl), moderate (30-59 mL/min CrCl), and severe (<30 mL/min CrCl) renal impairment with non-dialysis-dependent renal insufficiency (NDDRI).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Subjects with normal renal function given tirofiban Subjects with normal renal function (CrCl >90 mL/min) |
Drug: Tirofiban
A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
Other Names:
|
| Experimental: Subjects with moderate renal insufficiency given tirofiban Subjects with moderate renal insufficiency (CrCl 30-59 mL/min) |
Drug: Tirofiban
A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
Other Names:
|
| Experimental: Subjects with severe renal insufficiency given tirofiban Subjects with severe renal insufficiency (CrCl <30 mL/min). |
Drug: Tirofiban
A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- An analysis of tirofiban plasma concentration in normal, moderate and severe renal impaired adult subjects following a single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg). [Subject's participation in this study will last 3 days (confinement of 48 hours).]
Secondary Outcome Measures
- An analysis of platelet aggregation inhibition in normal, moderate and severe renal impaired adult subjects following a single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg). [Baseline (prior to administration of tirofiban), 15 minutes, 1 hour, and 6 hours following the end of the tirofiban administration.]
Other Outcome Measures
- A safety analysis of high-dose bolus tirofiban [Adverse events will be assessed on Day 1 (baseline), Day 2 (dosing) and Day 3 (study exit). For most subjects, no further assessment will occur after Day 3.]
To evaluate the safety profile in normal, moderate and severe renal impaired adult subjects following a single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg). Safety will be assessed for the duration of the subject's participation in the study which will last 3 days. If a serious adverse event is experienced the subject will be followed until the event resolves or the clinical course is stabilized. The most common adverse event associated with tirofiban is bleeding.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female 18-85 years of age. The mean age for the subjects with normal renal function (CrCl >90 mL/min) should match the mean age for the subjects with moderate or severe renal impairment (CrCl 30-59 mL/min, or CrCl <30 mL/min).
-
BMI ≥18.5 and ≤32.0.
-
Subjects who are able and willing to provide informed consent.
Exclusion Criteria:
-
Taking a medication from a Prohibited Medication List.
-
Active pericarditis.
-
Presumed or documented history of vasculitis.
-
Uncontrolled hypertension (blood pressure >180/110 mm Hg).
-
Dependency on renal dialysis.
-
Active internal bleeding or bleeding diathesis, surgery, trauma or gastrointestinal/genitourinary tract bleeding within 6 weeks prior to dosing.
-
Prior intracranial hemorrhage, hemorrhagic stroke, cerebrovascular accident (CVA) within 2 years or CVA with significant residual neurological deficit, intracranial neoplasm, arteriovenous malformation, intracranial aneurysm, or intracranial structural abnormality.
-
Thrombocytopenia (platelet count <100 x 10³ µL) or history of thrombocytopenia following heparin, tirofiban, or eptifibatide administration.
-
Taking Over-the-Counter (OTC) vitamins and/or herbal supplements including garlic oil supplements, fish oil supplements, ginger supplements or onion extract pills within 14 days before dosing.
-
Participation in another clinical trial 30 days prior to participation in the current study.
-
Any other condition that in the opinion of the Investigator may compromise the safety or compliance of the subject or would preclude subject successfully completing the trial.
-
Female subjects who have a positive pregnancy test at Screening or Admission (Day 1), or who are breastfeeding.
-
Inability to comply with the protocol for the duration of the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Avail Clinical Research, LLC | DeLand | Florida | United States | 32720 |
Sponsors and Collaborators
- Medicure
Investigators
- Principal Investigator: John Hill, MD, Avail Clinical Research, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Medicure 12001